Jump to content

Axcelead Boosts Integrated Drug Discovery Services for Biopharma with Genedata Screener

Leading Japanese solution provider for drug discovery extends use of automated screening data analysis platform to expand their offering of drug discovery screening with innovative screening technologies

June 2, 2020
Tokyo, Japan

Genedata, the leading provider of enterprise software solutions for biopharmaceutical R&D, today announced that leading Japanese solution provider in the drug discovery space Axcelead Drug Discovery Partners, a driver of innovation in research and Japan’s first provider of integrated drug discovery services, has expanded its license for Genedata Screener®, the market-leading solution for efficient and automated screening data analysis. Axcelead is adopting Genedata Screener to ramp up capacity for its R&D programs, and for routinely offering specialized services on modern screening technologies for thermal shift and ion channel screening.

“With Genedata Screener we can deliver what biopharma companies are searching for in a partner for drug discovery: fast completion of projects and the highest data quality,” said Junji Matsui, Head of Discovery Science at Axcelead. “Thanks to its capability to automate complex data analysis processes, Genedata Screener allows us to shorten data analysis time by an order of magnitude, and with best practices in data analysis built in, compliance with our clients’ stringent QC requirements is guaranteed. Genedata Screener also comes with broad support for modern screening technologies, so we now have one platform for all types of screening, which makes us more efficient.”

Genedata Screener has been developed to offer out-of-the-box analysis capability for a large variety of screening technologies, regardless of their data output, volume, and complexity. Two thirds of the world’s leading biopharmaceutical organizations—including almost all of Japan’s leading biopharmaceutical companies—already use Genedata Screener to automate, accelerate and streamline data analysis processes, with substantial savings in time, operational cost and system maintenance.  Regular updates ensure that Genedata Screener remains the solution of choice for research and development teams confronted with evolving data analysis needs and technologies.

“We are delighted to expand our relationship with Axcelead, the leading CRO for discovery services in Japan. We are proud that Axcelead has selected our Genedata Biopharma Platform for its strategy to deliver the highest quality services to its rapidly increasing customer base,” commented Othmar Pfannes, Ph.D., CEO of Genedata. “This collaboration is further proof of the value that our software can bring to the biopharma industry in its quest for innovation and efficiency.”

About Genedata

Genedata transforms data into intelligence with innovative software solutions that incorporate extensive biopharma R&D domain knowledge. Multinational biopharmaceutical organizations and cutting-edge biotechs around the globe rely on Genedata to digitalize and automate data-rich and complex R&D processes. From early discovery all the way to the clinic, Genedata solutions help maximize the ROI in R&D expenditure. Founded in 1997, Genedata is headquartered in Basel, Switzerland with additional offices in Boston, London, Munich, San Francisco, Singapore, and Tokyo.
LinkedIn | Twitter | YouTube


Allison Kurz
Public Relations


The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

All product and service names mentioned are the trademarks of their respective companies.

With Genedata Screener we can deliver what biopharma companies are searching for in a partner for drug discovery: fast completion of projects and the highest data quality

Junji Matsui
Head of Discovery Science